The integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF-β)

Carcinogenesis

Volumn 31, Issue 4, 2010, Pages 703-711

  Yang, Hyun ^a   Park, Seong Hwan ^a   Choi, Hye Jin ^a   Moon, Yuseok ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN HOMOLOGOUS PROTEIN; GLUCOSE REGULATED PROTEIN 78; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY DRUG ACTIVATED GENE 1 PROTEIN; PROTEIN KINASE R; SULINDAC SULFIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DDIT3 PROTEIN, HUMAN; DRUG DERIVATIVE; GDF15 PROTEIN, HUMAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH DIFFERENTIATION FACTOR 15; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PERK KINASE; SULINDAC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON TUMOR; DRUG EFFECT; ENDOPLASMIC RETICULUM; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; COLONIC NEOPLASMS; EIF-2 KINASE; ENDOPLASMIC RETICULUM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GROWTH DIFFERENTIATION FACTOR 15; HCT116 CELLS; HT29 CELLS; HUMANS; STRESS, PHYSIOLOGICAL; SULINDAC; TRANSCRIPTION FACTOR CHOP;

EID: 77950882798     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq008     Document Type: Article

References (62)

1. Rao, C.V. et al. (1995) Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55, 1464-1472.
2. Reddy, B.S. et al. (1996) Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56, 4566-4569.
3. Connolly, E.M. et al. (2002) Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br. J. Cancer, 87, 231-237.
4. Yoshida, S. et al. (2003) COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab. Invest., 83, 1385-1394.
5. Matsumoto, T. et al. (2006) Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adeno-matous polyposis. J. Gastroenterol. Hepatol., 21, 251-257.
6. Cruz-Correa, M. et al. (2002) Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology, 122, 641-645.
7. Lynch, H.T. et al. (1995) Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer, 75, 936-938.
8. Niv, Y. et al. (1994) Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology, 107, 854-857.
9. Tonelli, F. et al. (2000) Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J. Surg. Oncol., 74, 15-20.
10. Williams, C.S. et al. (1999) Sulindac sulfide, but not sulindac sulfone, in-hibits colorectal cancer growth. Neoplasia, 1, 170-176.
11. Bottone, F.G.Jr et al. (2005) The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol. Cancer Ther., 4, 693-703.
12. Marotta, A. et al. (2006) Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide. Int. J. Oncol., 28, 1471-1479.
13. Pangburn, H.A. et al. (2005) Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J. Carcinog., 4, 16.
14. Sinicrope, F.A. et al. (2005) Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol. Cancer Ther., 4, 1475-1483.
15. Brown, J.R. et al. (2005) COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol., 23, 2840-2855.
16. Grosch, S. et al. (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl Cancer Inst., 98, 736-747.
17. Kashfi, K. et al. (2005) Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem. Pharmacol., 70, 969-986.
18. Baek, S.J. et al. (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol., 67, 356-364.
19. Lee, E. et al. (2006) Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells. Exp. Mol. Med., 38, 325-331.
20. Johnen, H. et al. (2007) Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med., 13, 1333-1340.
21. Buckhaults, P. et al. (2001) Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res., 61, 6996-7001.
22. Fairlie, W.D. et al. (1999) MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J. Leukoc. Biol., 65, 2-5.
23. Hsiao, E.C. et al. (2000) Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol. Cell. Biol., 20, 3742-3751.
24. Welsh, J.B. et al. (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc. Natl Acad. Sci. USA, 100, 3410-3415.
25. Welsh, J.B. et al. (2001) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61, 5974-5978.
26. Brown, D.A. et al. (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin. Cancer Res., 9, 2642-2650.
27. Baek, S.J. et al. (2003) Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem., 278, 5845-5853.
28. Lamouille, S. et al. (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood, 100, 4495-4501.
29. Soto-Cerrato, V. et al. (2007) The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem. Pharmacol., 74, 1340-1349.
30. Shim, M. et al. (2005) Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J. Biol. Chem., 280, 18636-18642.
31. Moenner, M. et al. (2007) Integrated endoplasmic reticulum stress responses in cancer. Cancer Res., 67, 10631-10634.
32. Wek, R.C. et al. (2006) Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans., 34, 7-11.
33. Lee, A.S. (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res., 67, 3496-3499.
34. Oyadomari, S. et al. (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ., 11, 381-389.
35. Tsutsumi, S. et al. (2004) Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ., 11, 1009-1016.
36. Pyrko, P. et al. (2007) Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol. Cancer Ther., 6, 1262-1275.
37. Mohr, B. et al. (2005) Structural chromosomal aberrations in the colon cancer cell line HCT 116-results of investigations based on spectral karyotyping. Cytogenet. Genome Res., 108, 359-361.
38. Russo, P. et al. (1999) Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116. Ann. N. Y. Acad. Sci., 886, 252-256.
39. Gotoh, T. et al. (2002) Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP. J. Biol. Chem., 277, 12343-12350.
40. Jiang, H.Y. et al. (2004) Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol., 24, 1365-1377.
41. Chen, Y.L. et al. (2007) Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells. J. Pharmacol. Exp. Ther., 323, 746-756.
42. Kim, K.S. et al. (2002) Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology, 122, 1388-1398.
43. Vanderlaag, K. et al. (2008) 1, 1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res. Treat., 109, 273-283.
44. Sok, J. et al. (1999) CHOP-dependent stress-inducible expression of a novel form of carbonic anhydrase VI. Mol. Cell. Biol., 19, 495-504.
45. Wang, X.Z. et al. (1998) Identification of novel stress-induced genes down-stream of chop. EMBO J., 17, 3619-3630.
46. Jang, T.J. et al. (2004) Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis, 25, 1853-1858.
47. Yamaguchi, H. et al. (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem., 279, 45495-45502.
48. Chan, F.K. (2006) Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat. Clin. Pract. Gastroenterol. Hepatol., 3, 563-573.
49. Morris, A.J. et al. (1991) Small-bowel enteroscopy and NSAID ulceration. Lancet, 337, 1550.
50. Davies, N.M. et al. (1997) Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin. Pharmacokinet., 32, 437-459.
51. Duggan, D.E. et al. (1980) Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab. Dispos., 8, 241-246.
52. Ito, T. et al. (1999) RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J. Biol. Chem., 274, 15427-15432.
53. Liu, B.H. et al. (2006) Mycotoxin patulin activates the p38 kinase and JNK signaling pathways in human embryonic kidney cells. Toxicol. Sci., 89, 423-430.
54. Maggi, L.B.Jr et al. (2003) ERK activation is required for double-stranded RNA-and virus-induced interleukin-1 expression by macrophages. J. Biol. Chem., 278, 16683-16689.
55. Tarnawski, A.S. et al. (2003) Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J. Mol. Med., 81, 627-636.
56. Khomenko, T. et al. (2006) Suppression of early growth response factor-1 with egr-1 antisense oligodeoxynucleotide aggravates experimental duodenal ulcers. Am. J. Physiol. Gastrointest. Liver Physiol., 290, G1211-G1218.
57. Jones, M.K. et al. (1999) Gastrointestinal mucosal regeneration: role of growth factors. Front. Biosci., 4, D303-D309.
58. Braddock, M. (2001) The transcription factor Egr-1: a potential drug in wound healing and tissue repair. Ann. Med., 33, 313-318.
59. Liu, C. et al. (1998) Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther., 5, 3-28.
60. Moon, Y. et al. (2007) Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells. Toxicol. Appl. Pharmacol., 223, 155-163.
61. Moon, Y. et al. (2008) Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways. Life Sci., 82, 591-599.
62. Sun, Y. et al. (2005) Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol. Cancer Ther., 4, 51-59.